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Abstract: The control of osteoblast/osteoclast cross-talk is crucial in the bone remodelling process
and provides a target mechanism in the development of drugs for bone metabolic diseases.
Osteoprotegerin is a key molecule in this biosignalling pathway as it inhibits osteoclastogenesis
and osteoclast activation to prevent run-away bone resorption. This work reports the synthesis of a
known osteoprotegerin peptide analogue, YCEIEFCYLIR (OP3-4), and its tagging with a gadolinium
chelate, a standard contrast agent for magnetic resonance imaging. The resulting contrast agent
allows the simultaneous imaging and treatment of metabolic bone diseases. The gadolinium-tagged
peptide was successfully synthesised, showing unaltered magnetic resonance imaging contrast
agent properties, a lack of cytotoxicity, and dose-dependent inhibition of osteoclastogenesis in vitro.
These findings pave the way toward the development of biospecific and bioactive contrast agents
for the early diagnosis, treatment, and follow up of metabolic bone diseases such as osteoporosis
and osteosarcoma.
Keywords: osteoclastogenesis; RANK-RANKL-OPG; mimetic peptide; Gadolinium chelate; MRI
1. Introduction
The physiological remodelling of bone tissue is controlled by a delicate balance between the
activity of the cells producing its mineralised extracellular matrix, the osteoblasts, and that of the
osteoclasts, the cells responsible for its resorption [1,2]. This process of tissue turnover is regulated
through the interaction of the receptor activator of nuclear factor kappa-B (RANK), expressed by
osteoclast progenitors, with its cognate ligand (RANKL), which is expressed by the osteoblasts either
as a membrane-bound form or as a free-soluble form. The soluble form activates both osteoclast
differentiation and activation, thus initiating bone resorption [2]. A fine regulation of the cross-talk
between these two cells is provided by the synthesis of another protein, osteoprotegerin (OPG), a soluble
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receptor for RANKL that is secreted by osteoblasts and bone marrow stromal cells to decoy the
recognition of RANK by RANKL [3]. By binding RANKL, OPG prevents the ligand recognition of RANK,
thus inhibiting osteoclast differentiation and activity and allowing new bone tissue deposition [4].
Indeed, the balanced sequence of interactions of the RANK/RANKL/OPG triad represents a
tightly controlled system at the centre of the osteoclast-osteoblast functional unit that determines
skeletal mass at any time in an organism’s life. It is well established that the dysregulation of the
RANK/RANKL/OPG triad significantly affects osteoclast maturation, survival, and activity, resulting
in disorders of the bone remodelling cycle such as osteoporosis, Paget’s disease, rheumatoid arthritis,
and bone metastases [5,6]. Current pharmacological interventions are designed to either reduce bone
resorption or stimulate bone formation. Drugs used to reduce bone resorption include hormone
replacement therapy (HRT) and selective oestrogen receptor modulators (SERM), bisphosphonates and
those used to increase bone formation include teriparatide (PTH 1-34), and strontium renalate [7,8].
However, these drugs have associated side effects such as hot flashes, osteonecrosis, and poor fracture
healing and osteointegration [8]. Moreover, as RANKL plays other physiological roles including
immune function, lymph node formation, and mammalian development [9], the development of
therapeutic drugs that can replace its use with no side effects is desirable. One of the notable
developments in this regard is the recently approved drug, Denosumab, a fully human monoclonal
anti-RANK antibody that mimics the activities of OPG, which is used as a bone anti-resorptive
agent [10,11]. However, this drug is expensive to produce and store, carries the risk of viral and
prion contamination, and its effect on immune function is unclear [11]. For these reasons, the use of
small molecules which are able to target remodeling pathways has been advocated [12]. To this end,
peptides such as the gap-junction protein (connexin 43) mimetic (GAP27) [13], the RANK-mimetic
peptide [14], the OPG-mimetic peptides [15], the TNF-[alpha] and the RANKL antagonist peptide [16],
and a TNF receptor loop peptide mimic [17] have been identified as able to reduce bone resorption
and/or promote bone formation.
This work reports the synthesis of a known bone specific cyclic OPG-mimetic peptide (OP3-4)
sequence YCEIEFCYLIR, which is based on residues 113–122 of the human OPG sequence [15,18,19],
and its complexation with a contrast agent for magnetic resonance imaging (MRI), gadolinium, through
a chelating moiety, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) [20]. The novel
peptide formed, DOTA-Gd-OP3-4, was tested for MRI traceability and its direct inhibitory effect
on osteoclastogenesis in vitro to offer a novel theranostics agent with the potential to enable the
simultaneous diagnosis (or follow up) and treatments of bone affected by metabolic diseases.
2. Materials and Methods
2.1. Materials
Amino acids protected by 9-fluorenylmethyloxy carbonyl (Fmoc) where purchased from
NovaBiochem, Watford, UK. Tenta Gel S NH2 resin and Rink amide linker were purchased
from Iris Biotech, Marktredwitz, Germany. Dimethylformamide (DMF), dichloromethane, diethyl
ether, and methanol were of analytical grade (≥99.5%) and obtained from Fisher Scientific,
Loughborough, UK. Triisopropylsilane (TIPS, ≥98.0% GC), phenol (≥99%), trifluoroacetic acid
(TFA, ≥99%), and N,N-diisopropylethylamine (DIPEA, ≥99%) were obtained from Iris Biotech GmbH.
2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU, ≥97%) was
purchased from NovaBiochem, UK. Tri-tert-butyl 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate
(DOTA-tri-t-Bu-ester) was purchased from Sigma Aldrich, Dorset, UK. All other reagents were of
analytical grade.
2.2. Synthesis of Peptides
The peptides OP3-4 and DOTA tethered OP3-4 (DOTA-OP3-4) were synthesised by solid-phase
peptide synthesis (SPPS) using the conventional Fmoc protection/deprotection strategy on Tenta Gel
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S NH2 resin (0.1 mmol equivalent) with DMF as the reaction solvent. The resin was pre-swollen in
7 mL DMF in a 10 mL reaction vessel and the peptides synthesised by first attaching an acid-liable
Fmoc-Rink Amide linker to the resin followed by sequential amino acid coupling and deprotection
steps as per peptide sequence. HBTU and DIPEA were used for the coupling reaction (×2, 30 min,
room temperature) at one and two times the concentration of the amino acids and 20% (v/v) piperidine
in DMF was used for deprotection (2 min, ×3). In all preparations, the resin, linker, and amino acids
were added in the molar ratio of 1:4:4, respectively. Each coupling or deprotection step was followed
by washing steps (×3 with DMF). After the final deprotection step, the resin was washed with 10 mL
DMF (×3), dichloromethane (×4), methanol (×4), and diethylether (×4). The peptides were then dried
in a vacuum oven at room temperature until reaching a constant weight (~2 h) and stored at 4 ◦C for
further studies.
In the synthesis of DOTA-OP3-4 (Figure 1), Fmoc-Lys (Mtt)-OH was first coupled to the Rink-amide
linker. The Mtt (4-methyltrityl) protecting group was then removed by a series of washes (1 min, ×9)
with 1% TFA (v/v) in DMF until clear; Mtt appears yellow in DMF solution. DOTA-tri-t-Bu-ester
was then coupled to lysine, followed by the deprotection of the Fmoc protected terminal on lysine.
Two glycine amino acids were then sequentially coupled as spacers, followed by the subsequent
addition of amino acids as per the OP3-4 sequence (Figure 1).
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The peptides were freed from the resin by incubation in a cleavage solution (88% TFA, 5% H2O,
5% phenol and 2% TIPS) for 3 h at room temperature. The cleaved peptides were filtered through
glass wool, precipitated, and isolated by a series of washing and centrifugation steps in cold
diethylether (≤4 ◦C). The samples were then dried over a stream of nitrogen gas and stored at
−20 ◦C. Crude peptides were dissolved in 0.1% formic acid in methanol at 2 mg/L and characterised
on an ion trap mass spectrometer (ITMS) model HTC Plus and a Time-of-Flight mass spectrometer
(TOF-MS) model MicrOTOF, both from Bruker Daltonics (Billerica, MA, USA). The systems were
optimised for the detection of the peptide m/z in every instance and once the peptide was characterised,
the systems were re-optimised for the isolation and collection of the purified peptide. Data acquisition
was carried out by Compass 1.1, Esquire 5.3, and Hystar 3.1 software (Bruker Daltonics, Billerica,
MA, USA).
2.3. yclisation of P i etic Peptides
P3-4 and T - P3-4 ere cyclised by di ethyl sulfoxide ( S ) oxidation to for
cysteine-cysteine disulfide bonds as described in the literature [21], ith slight odification. Briefly,
peptides (1 g) ere dissolved in 60 L of oxidising buffer (100 a 2P 4 and 2 dn· l,
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5% DMSO, pH 7.0) and shaken for 12 h. The solution was then acidified with 1 M HCOOH (250 µL)
and the peptides purified and analysed by hydrophilic interaction liquid chromatography (HILIC)
coupled to ITMS (LC-MS). Cyclisation (disulfide bridge formation) was confirmed by the quantitation
of free thiol groups using Ellman’s reagent following kit instructions (Invitrogen Molecular Probes
T6060 Thiol and Sulfide Quantitation Kit, from ThermoFisher Scientific, Loughborough, UK) [22].
2.4. Gadolinium Chelation into DOTA-OP3-4
Cyclised DOTA-OP3-4 (1 mmoles, in 2 mL ethanol) was mixed with GdCl3·6H2O (1 mmol) in
5 mL water and the pH adjusted to 6.5 with Na2CO3 (0.1 mL) and stirred for 15 h at 60 ◦C. The peptides
were then purified by high pressure liquid chromatography (HPLC) using a Solvent A (methanol,
0.1% TFA) and Solvent B (water, 0.1% TFA) gradient from 5% to 60% solvent. The system was coupled
to the non-destructive soft-ionisation electrospray ITMS.
2.5. Chromatographic Separation of the Peptides by LC-MS
The peptide synthesis products were separated by HILIC on an HP 1200 HPLC (Agilent
Technologies, Santa Clara, CA, USA) equipped with a TSK-Gel Amide 80 HILIC column (250 mm
(length) × 4.6 mm internal diameter and 5 µm particle size) from TOSOH Bioscience (Tokyo, Japan).
The system used a binary mobile phase of solvent A (acetonitrile, 0.1% (v/v) formic acid) and solvent
B (water, 0.1% (v/v) formic acid) at a flow rate of 300 µL/min. The gradient elution program was:
0–50% solvent B for 0–20 min for OP3-4 and 5–90% solvent B for 0–45 min for both DOTA-OP3-4
and DOTA-Gd-OP3-4. The peptides were dissolved in 0.1% (v/v) formic acid in methanol at 20 µg/g
and the injection volume was 100 µL. The tube from the column was divided into two channels
of equal length and diameter, with one leading to the detector (ITMS) while the other led to the
sample-collecting vessel where purified peptides were collected at the point of detection. The purified
peptides were lyophilized and stored at −20 ◦C.
2.6. Tandem MS
ITMS was first optimised to detect the putative ions from the SPPS products in the full scan mode,
followed by their isolation in the single ion monitoring mode (SIM). Energy was then applied to the
system to fragment the isolated putative ion (MS/MS or MS2) and the resulting fragmentation products
were scanned in product ion mode. Depending on the intensity and amount of the fragmentation
products from MS/MS, the most intense fragment (base peak) was isolated and fragmented further
(MS3), which made further confirmation of the identity of the peptide possible. The process was
repeated with subsequent base peaks until the obtained peaks were within the noise signal.
2.7. MRI Analysis
The peptides (DOTA-OP3-4 and DOTA-Gd-OP3-4) were first dissolved in a minimum volume
of DMSO and then diluted to a desired peptide concentration (0–10 µg/mL and 0.5% by volume
DMSO) in phosphate-buffered saline (PBS) and the pH adjusted to 7.2 using 0.1 M HCl. DOTA-Gd
and DOTA-OP3-4 were used at 10 µg/mL as the positive and negative controls, respectively.
The DOTA-Gd-OP3-4 sample was then double diluted ten times from 10 µg/mL to 0.005 µg/mL
and each sample (1 mL) was placed into different wells of a 24-well tissue culture plate for MRI
analysis. The analysis was performed in T1 weighted scan mode using the Siemens AVANTO 1.5T
MRI scanner with parameters set as: echo time (TE) 13, repetition time (TR) 200, and SL 1 mm.
The analysis was conducted at the Clinical Imaging Science Centre, Brighton and Sussex Medical
School, Brighton, UK.
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2.8. Cell Viability Studies
Osteoblastic cells, the SaOS-2 cell line (ATCC, Manassas, VA, USA), were cultured to 85% confluence
in McCoy’s 5A culture medium (without L-glutamine) supplemented with 10% foetal bovine serum
(PAA Laboratories GmbH, Cölbe, Germany). The cells were then trypsinised (5 mL trypsin, 37 ◦C for
6 min), washed, and seeded into 96-well plates at a 104 cells/well seeding density. The cells were then
treated with different peptide concentrations (0–200 µM) and incubated (37 ◦C, 5% CO2) for 24 h,
after which the cell viability and cytotoxicity were evaluated.
Cell viability was studied by assessing the ability of the cells to metabolically reduce a tetrazolium
salt 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS)
to a soluble formazan derivative following kit instructions (CellTiter 96® AQueous One Solution Cell
Proliferation Assay from Promega, Southampton, UK), with slight modification. Briefly, cells in a
96 well plate were washed three times with PBS and re-supplemented with 100 µL of culture medium
per well. MTS/PMS (20 µL) solution (1:20 v/v) was then added to each well and the cells incubated
for 2 h. Control cells were not exposed to peptides. The amount of formazan produced (purple colour)
was measured at an absorbance wavelength of 490 nm using the Biochrom Asys UVM 340 plate reader
equipped with Micro Win 2000 software (Biochrom Ltd., Cambridge, UK).
Cytotoxicity of the peptides was studied by assessing the amount of lactate dehydrogenase (LDH)
released from cells as a measure of the number of lysed cells following kit instructions (CytoTox
96® Non-Radioactive Cytotoxicity Assay, Promega, UK). Briefly, after peptide treatment, cell culture
medium isolated from every well was centrifuged (2000 rpm, 5 min) and the debris-free supernatant
transferred to a clean 90 well plate. CytoTox 96® Reagent (100 µL) was added to each well and incubated
for 30 min. The kit stop solution was added and absorbance measured at 490 nm. Positive control cells
were completely lysed with Triton-X before centrifugation to estimate the maximum toxicity value
in the same culture conditions measured as total LDH into the tissue culture supernatant. Negative
control cells were not lysed. All control cells were not exposed to peptides.
Epi-fluorescence microscopy analysis for viable cells in cultures treated with 100 µM of each
peptide was performed after Hoechst 33,258/Propidium iodide (H/PI, from Invitrogen, Carlsbad, CA,
USA) nuclear staining (50 ng/mL) at an H:PI ratio of 1:1 per well in a 24 well culture plate. Diffusely
H positive nuclei (blue and live) and diffusely PI positive nuclei (pink and dead) were counted and
the number of live cells was presented as a percentage of the total number of cells per field. At least
200 cells from different randomly picked areas were counted per well.
2.9. Monocyte Isolation and Osteoclastogenesis Studies
Ethical approval for human blood studies was acquired from the University of Brighton Faculty
Research Ethics and Governance Committee, Brighton, UK. Human whole blood (6 mL) from healthy
consented volunteers was layered on Histopaque (3 mL, density: 1.077 g/mL, from Sigma Aldrich,
UK) in heparinised tubes (9 mL Vacuette NH Sodium Heparin, Greiner Bio-One International GmbH)
and centrifuged (450× g, 30 min). The monocyte-rich buffy coat layer was isolated by gentle pipette
aspiration and washed in 8 mL PBS (×3) by centrifugation (250× g, 15 min) to remove the platelet-rich
plasma fraction. The cells were then resuspended in 1 mL αMEM (PAA Laboratories GmbH, Germany)
medium and seeded into 24 well plates at a 5 × 105 cells/well seeding density. After a 3-h incubation
(37 ◦C, 5% CO2), non-adherent cells were rinsed with PBS (×3) and the adherent cells cultured for 24 h
in αMEM medium supplemented with 10% (v/v) FBS and Penicillin/Streptomycin (1×).
Monocyte differentiation into osteoclasts was induced by spiking the cells with human
recombinant RANKL (rh RANKL) and Macrophage Colony Stimulating Factor (rh M-CSF), both
purchased from Invitrogen, UK. Firstly, monocytes were treated with different concentrations of
rh RANKL (0, 10, 50, and 100 ng/mL) in the presence of 25 ng/mL rh M-CSF and over different
time periods (two, four, and six days). Osteoclastogenesis inhibition was then studied by culturing
monocytes in αMEM medium supplemented with 10% (v/v) FBS, Penicillin/Streptomycin (1×),
50 ng/mL rh RANKL, and 25 ng/mL rh M-CSF for four days in the presence or absence of 50 µM
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peptides (OP3-4, DOTA-OP3-4 and DOTA-Gd-OP3-4). The positive control was treated with rh
OPG (50 ng/mL) and the negative control had no treatment. The degree of osteoclastogenesis was
assessed by tartrate-resistant acid phosphatase (TRAP) staining using a commercial kit (387A for
cytochemical staining from Sigma Aldrich, UK) according to the manufacturer’s instructions. TRAP
positive multinucleated cells were counted using a Nikon Eclipse Ti-U microscope equipped with a
Nikon DIGITAL SIGHT DS-Fi1 camera (Nikon Corporation., Tokyo, Japan) and NIS-Elements BR 3.2
software (Nikon Corporation., Tokyo, Japan) was used to count the cells in six different randomly
selected areas in each well.
3. Statistical Analysis
All statistical analyses were performed by using analysis of variance (ANOVA) (software: Minitab
Version 15, Minitab Inc, State College, PA, USA). Whenever ANOVA indicated the groups were
significantly different, a t-test for independent samples was performed. Samples were considered
significantly different at p ≤ 0.05.
4. Results and Discussion
4.1. Peptide Synthesis and Characterisation
Due to the lack of peptide standards for comparative verification of the successful synthesis of
the putative peptides, two mass spectrometry analysis approaches were used: (1) TOF-MS, to benefit
from its high mass resolution and accuracy (up to five decimal places), high linearity, and wide scan
range (50 to 3000 m/z); and (2) ITMS, to benefit from its high sensitivity and capacity to sequentially
trap and fragment desired ions so as to identify the building units of a molecule that would confirm
successful synthesis.
The MS acquisition for the putative peptides was first performed in full scan mode using TOF-MS,
providing an overview of the products. The theoretical m/z of the peptides and their respective
fragment ions were generated using the MS-product tool of the online program ProteinProspector
V5.10.0. [23]. Successful cyclisation through the cysteine-cysteine disulfide bridge formation was
confirmed by the absence (95% reduction) of free thiol groups in both OP3-4 and OP3-4-DOTA after
the oxidation reaction (data not shown).
The molecular structure and mass spectra of the OP3-4 peptide (m/z 1450.7) synthesis products
acquired by TOF-MS are shown in Figure 2A, where the putative ions [M + 2H]2+ (m/z 725.87, base peak)
and [M + H]+ (m/z 1450.68) are annotated. Although incomplete fragments were seen in the spectra
of OP3-4, the fragments were not sufficiently abundant to allow their conclusive identification from
the background noise. The analysis of the synthesis products of the novel DOTA-OP3-4 peptide by
TOF-MS showed numerous undesired product ions. As a result, ITMS, with its ability to trap specific
desired ions using the single ion mode (ITMS-SIM), was used to confirm the presence of the putative
ion. The full scan MS spectrum of the synthesis products of the novel DOTA-OP3-4 peptide (m/z 2080.2)
showed ions with m/z 694.1 (base ion) and m/z 1040.5, which correspond to the putative peptide ions
[M + 3H]3+ and [M + 2H]2+, respectively (Figure 2B). The introduction of a lysine-glycine-glycine
spacer between the OP3-4 sequence and the DOTA moiety in DOTA-OP3-4 was essential to avoiding
potential steric hindrance during the synthesis and to maximise the exposure of the peptide to the
relative cell receptor. The numerous product ions observed in the MS spectra of DOTA-OP3-4 may be
the effect of using 0.1% (v/v) TFA in the presence of the cysteine-rich peptide during the additional
step to remove lysine protecting groups (Mtt) and the subsequent coupling of DOTA. The interaction
of both the terminal carboxyl groups on the growing peptides and of the DOTA moiety with the side
chain groups on the peptide during the synthesis and the cleavage steps may also have led to intra-
and intermolecular interactions, resulting in numerous incomplete and undesired peptidic chains.
The analysis of the OP3-4 peptide by LC-MS showed the peptide to account for 80% of the crude
synthesis products and a purity of >98% could be achieved after LC-MS purification with ITMS as
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the detector (Figure 3A). Despite the presence of numerous intense peaks corresponding to undesired
ions, the ion corresponding to DOTA-OP3-4 was found to account for 60% of the crude synthesis
products by LC-MS. This disparity in the intensity of the synthesis products by TOF-MS and LC-MS
coupled to ITMS could be due to differences in the volatility of the ions in the MS [24] as smaller
molecules are more volatile than larger ones in MS. Although TOF-MS gives highly accurate m/z for
the ions, the system is not as sensitive as the ITMS. Since ITMS allows for optimisation of the detection
of the desired ions within a specified m/z range, and LC-MS separates molecules according to their
polarity, a more accurate result of the purity and/or yield of the synthesis could be obtained. Indeed,
after isolation of the putative ion, DOTA-OP3-4 was found to account for >95% of the isolated product
(Figure 3B).
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Successful chelation of the gadolinium ion (Gd3+) onto purified DOTA-OP3-4 to produce
DOTA-Gd-OP3-4 (Figure 4A) was confirmed by LC-MS, where the peak with m/z 694.1 for DOTA-OP3-4
peptide shown in Figure 3B was replaced by a base peak with m/z 714.8, corresponding to the ion
[M + 3H]3+ of DOTA-Gd-OP3-4 after the chelation of Gd3+ (Figure 4B). LC-MS allowed the isolation
of the peptide from salts, non-chelated Gd3+, and other synthesis products, and the analysis of the
purified DOTA-Gd-OP3-4 sample showed no evidence of residual free Gd3+ ions.
Gadolinium is a lanthanide metal commonly used in clinics as an MRI contrast agent. Gadolinium
is used in its ionic form chelated by large, non-toxic linear or macrocyclic organic molecules that
form stable and biochemically inert gadolinium contrast agents (GCA). This sequestration of Gd3+
with organic chelates circumvents the known toxicity of free Gd3+ in humans and ensures their
excretions from the body through kidney clearance. However, these GCA, in particular those of linear
chelates such as Omniscan (gadodiamide), Magnevist (gadopentetate dimeglumine), and Optimark
(gadoversetamide), are associated with slow excretion rates due to accumulation within the body
(i.e., in the liver) and toxicity from free Gd3+ ion release due to transmetallisation with Zn2+, Cu2+,
and Ca2+ in vivo [25,26]. Macrocyclic GCAs such as dotarem (Guerbet) and gadovist (Bayer Schering
Pharma AG) are less toxic as they bind Gd3+ more tightly and are more stable with low dissociation
rates than linear chelates. However, these GCAs, like linear ones, are associated with short circulation
in the body and inefficient discrimination between diseased and normal tissue seen in use of low
molecular diethylenetriaminepentaacetic (DTPAs) [25,26].
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(B) Chromatographic separation profile of the purified DOTA-Gd-OP3-4. The ITMS spectra of the
ions eluted in peak 1 (putative peptide) and peak 2 (contaminating fraction) are also shown (bottom).
The purity of the peptide, estimated by integration of the peak areas, was >90%.
Through this work, tissue-specific imaging may be improved by the incorporation of a peptide
sequence specific for the cross talk of bone cells, the RANK-RANKL pathway, and the potential
toxicity of Gd3+ is circumvented by the use of DOTA, a macrocyclic chelate for Gd3+ [27]. Indeed,
som DOTA-based Gd contras agents are FDA approved and are among the most widely used contrast
agents i clinica imaging with well-established safety and MRI effi acy [27,28].
In the chelation of Gd3+ into DOTA-OP3-4, the DOTA moi ty acts as a polydentate ligand
and envelops the metal cations, in this c se complexing Gd3+, to give an MRI visible peptide.
Nanomaterials 2018, 8, 399 9 of 15
The coordination of the DOTA ligands and metal ion in the complex depends on the conformation
of the ligand and geometric tendencies of the metal cation [29,30]. On its own, DOTA acts as an
octadentate ligand, binding the metal through four amino and four carboxylate groups. In this study,
the DOTA molecule acts as a septadentate since one of the carboxylate groups is used in the formation
of a covalent bond with the peptide. However, a carboxylate group from the amino acid linking DOTA
and the peptide provides the eighth ligand and restores the octadentate state, forming a highly stable
coordination complex [30].
Analysis of the result obtained from a T1 weighted MRI scan confirmed the successful chelation
of Gd3+, with DOTA-Gd-OP3-4 producing a brighter signal than DOTA-OP3-4, which had a signal
similar to the sample with PBS solutions only (Figure 5). Moreover, the intensity of the T1 signal from
DOTA-Gd-OP3-4 samples was directly proportional to the concentration of the peptide.
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Figure 5. T1 weighted MRI scan of DOTA-Gd-OP3-4 showing a concentration-dependent signal
intensity. The peptides, pre-dissolved in DMSO, were diluted to the desired concentration in PBS
buffer (1 mL) and the MRI signal acquired at the same time using the parameters: SL5, TE 8.7, and
TR550. DOTA-Gd (MW 557.64 g/mol) and DOTA-Gd-OP3-4 (MW 2141.4 g/mol) were prepared at a
concentration of 1 µg/ml, corresponding to 1.79 µM and 0.47 µM Gd, respectively.
The coordination of the DOTA ligands and metal ion in the complex depends on the conformation
of the ligand and geometric tendencies of the metal cation [29,30]. On its own, DOTA acts as an
octadentate ligand, binding the metal through four amino and four carboxylate groups. In this study,
the DOTA molecule acts as a septadentate since one of the carboxylate groups is used in the formation
of a covalent bond with the peptide. However, a carboxylate group from the amino acid linking DOTA
and the peptide provides the eighth ligand a d restores the octa enta e stat , forming a highly stable
coordination complex [30].
Although the potential theranostic benefits of the developed peptide are clear, the minimum
peptide concentration that would be required for a visible change in the MRI signal intensity in vivo
remains to be determined through future relaxivity studies [31,32]. Indeed, relaxivity calculation
requires the different concentrations of the peptide to be analysed separately in T1 and T2 modes and
using the respective r1 and r2 to determine relaxivity [31–33]. Although the in vivo relaxivity and safety
of the DOTA-Gd moiety are well-established, [28,32,34], the new peptide complex presents a different
immedi te molecular environment that can affect the MRI profile of Gd3+ [35,36]. The importance of
relaxivity studies in vivo is supported by the effect that the molecular environment has on the MRI
profile, leading investigators to questio the clinical efficacy of T1 relaxivity measurements p rformed
in vitro in simple media and temperatures different from those of living tissue [32–34,36].
In addition, although TOF-MS and LC-MS demonstrated the successful synthesis of peptides,
it was necessary to perform tandem MS for additional confirmation of the results due to the lack of
standards. The ions to be fragmented were acquired in product ion scan mode, isolated, and further
fragmented to produce smaller units that allowed peptide identification and the confirmation of
successful synthesis. In all cases, the voltages for the optimal transfer of the ions from the LC into
the ion trap, their stabilisation in the trap, and fragmentation were opt mised. A list of the peptides,
isolated ions thereof (SIM), and fragmentation products are given in Table 1.
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Table 1. Tandem MS of OP3-4 and DOTA-OP3-4 peptides using ITMS.
TOF-MS (Full Scan MS) ITMS MS-MS Product Ions (Ion Trap)
Peptide (m/z) TentativeAssignment SIM (m/z)
MS/MS Product
Ion (m/z)
Tentative
Assignment
MS/MS Scan
Range
OP3-4
1451.6960 [M + H]+ 500–1500
726.377808 [M + 2H]2+ 726 886 b7-2H 300–1200
733 b6-H2O
715 b6-2H2O
564 y4
DOTA-OP3-4
1040.52070 [M + 2H]2+
694.01938 [M + 3H]3+ 694 987 300–1200
691 b11-2H2O-NH32+
596
514 y72+
458 y62+
401 y52+
4.2. The Effect of the Peptides on Cell Viability and Osteoclastogenesis
The effects that the peptides have on cells was first studied by spiking SAOS-2 cells with different
concentrations of OP3-4. MTS and LDH assay results showed cell viability within a wide range of
peptide concentrations (Figure 6A). The H/PI study of the effect of OP3-4-DOTA and OP3-4-DOTA-Gd
on the SAOS-2 cells relative to OP3-4 at a fixed concentration (100 µM) showed no significant effect on
cell viability (Figure 6B). Although there appears to be a decrease in cell viability from the control to
OP-3-4 to DOTA-OP3-4 and DOTA-Gd-OP3-4, the differences were not significant to the control and
across the different treatment groups (p > 0.05).
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Figure 6. OP3-4, DOTA-OP3-4, and DOTA-Gd-OP3-4 have no significant effect on the viability of
SAOS-2 cells. (A) The cells were cultured with different concentrations of OP3-4 peptide for 24 h
and the percentage of de d and liv cells determined by assaying fo LDH in supernatant nd MTS
assay, respectively. Absorbance was measured at 490 nm. (B) The effect of derivatise OP3-4 peptides
(at 100 µM) on cell viability was determined by fluorescence microscopy after H/PI live and dead cell
staining (B). Data is mean ± SE, n = 6.
4.3. Osteoclastogenesis Inhibition Studies
The studies conducted to ass ss the effect of cytokine (rh RANKL and rh M-CSF) concentration
over two, four, and six days in culture showed that the amount of TRAP-positive giant multinucleated
cells (MNC) per well increased with the increase of both cytokine (rh RANKL) concentration and
culturing time (Figure 7A). The number of TRAP-positive MNCs increased significantly after four
days in cultures treated with 50 ng/mL and 100 ng/mL rh RANKL. However, osteoclastogenesis in
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cultures treated with 50 ng/mL rh RANKL was not significantly different from 100 ng/mL at day 4
and 6 (p > 0.05). As such, the rh RANKL concentration of 50 ng/mL and a culture time-period of four
days were adopted for studies on osteoclastogenesis inhibition by the peptides.
Representative images of the cells after four days of culture in the presence or absence of the
cytokines and in the presence or absence of the peptides are given in Figure 7B. The cells that did
not receive cytokines and those treated with rh RANKL only were TRAP negative, morphologically
small, and round, with a tendency to form clusters (Figure 7B(i and ii)). However, the fact that
this clustering phenomenon was observed in cells that did not receive either cytokine suggests
that it could be due to other factors apart from rh M-CSF and/or RANKL and more studies are
necessary to clarify that. On the other hand, the cells treated with only rh M-CSF were TRAP negative
and morphologically narrow and stretched (Figure 7B(iii)), while those treated with both cytokines
differentiated into cells that were much larger (>×10), multinucleated, morphologically irregular, and
TRAP positive (Figure 7B(iv)). This is consistent with the established knowledge that M-CSF and
RANKL induce the migration of monocytes towards each other, resulting in cell fusion to produce
a giant osteoclast like TRAP-positive MNC [37–39]. The size and amount of TRAP-positive MNCs
was seen to reduce in cultures treated with the peptides (Figure 7B(v–vii)) and in the positive control
(rh OPG) (Figure 7B(viii)). This result was also quantitatively confirmed by counting the number of
TRAP-positive cells with each respective treatment (Figure 7C). The observed potency of OP3-4 in
osteoclastogenesis inhibition is consistent with previous findings [17,18] and was significantly higher
than that observed for DOTA-OP3-4 and DOTA-Gd-OP3-4. However, all the peptides significantly
reduced the RANKL/M-CSF-induced osteoclastogenesis.
Nanomaterials 2018, 8, x  11 of 14 
 
receive cytokines and those treated with rh RANKL only were TRAP negative, morphologically 
small, and round, with a tendency to form clusters (Figure 7B (i and ii)). However, the fact that this 
clustering phenomenon was observed in cells that did not receive either cytokine suggests that it 
could be due to other factors apart from rh M-CSF and/or RANKL and more studies are necessary to 
clarify that. On the other hand, the cells treated with only rh M-CSF were TRAP negative and 
morphologically narrow and stretched (Figure 7B(iii)), while those treated with both cytokines 
differentiated into cells that were much larger (>×10), multinucleated, morphologically irregular, and 
TRAP positive (Figure 7B(iv)). This is consistent with the establish d knowledge that M-CSF and 
RANKL induce the migration of monocytes towards each other, resulting in cell fusion to produce a 
gia t osteoclast like TRAP-positiv  MNC [37–39]. The size and amount of TRAP-positive MNCs was 
seen to reduce in cultures treated with the peptides (Figure 7B(v–vii)) and in the positive control (rh 
OPG) (Figure 7B(viii)). This result was also quantitatively confirmed by counting the number of 
TRAP-positive cells with each respective treatment (Figure 7C). The observed potency of OP3-4 in 
osteoclastogenesis inhibition is consistent with previous findings [17,18] and was significantly higher 
than that observed for DOTA-OP3-4 and DOTA-Gd-OP3-4. However, all the peptides significantly 
reduced the RANKL/M-CSF-induced osteoclastogenesis. 
 
Figure 7. (A) Graphical representation of the effect of rh RANKL concentration and time in culture 
on osteoclastogenesis. (B) The effect of peptides on osteoclastogenesis after a four-day culture with (i) 
no cytokines or peptides, (ii) rh RANKL only, (iii) rh M-CSF only, (iv) rh RANKL and rh M-CSF, (v) 
OP3-4, (vi) DOTA-OP3-4, (vii) DOTA-Gd-OP3-4, and (viii) rh OPG (positive control): iv–ix had rh 
RANKL (50 ng/mL) and rh M-CSF (25 ng/mL). (C) Graphical representation of osteoclastogenesis 
inhibition by OPG mimetic peptides. 
Indeed, the presentation and binding of the developed OPG mimetic peptides to RANK may 
have been specific and sufficient to inhibit RANK-RANKL interaction. It is well established that 
although the molecules of the TNF superfamily (TNFSF), to which RANK and RANKL belong, are 
similar in structure, several members of this cytokine family show significant sequence diversity [40]. 
Consistent with this observation, studies on the 3D structures and mechanism of members of the 
Figure 7. (A) Graphical representation of the effect of rh RANKL concentration and time in culture
on osteoclastogenesis. (B) The effect of peptides on osteoclastogenesis after a four-day culture with
(i) no cytokines or peptides, (ii) rh RANKL only, (iii) rh M-CSF only, (iv) rh RANKL and rh M-CSF,
(v) OP3-4, (vi) DOTA-OP3-4, (vii) DOTA-Gd-OP3-4, and (viii) rh OPG (positive control): iv–ix had rh
RANKL (50 g/mL) and rh M-CSF (25 ng/mL). (C) Graphical representation of osteoclastogenesis
inhibition by OPG mimetic peptides.
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Indeed, the presentation and binding of the developed OPG mimetic peptides to RANK may have
been specific and sufficient to inhibit RANK-RANKL interaction. It is well established that although
the molecules of the TNF superfamily (TNFSF), to which RANK and RANKL belong, are similar in
structure, several members of this cytokine family show significant sequence diversity [40]. Consistent
with this observation, studies on the 3D structures and mechanism of members of the TNFSF such as
TNFα [41], TNF-β [42], RANKL/RANK [43,44], sTNF-R1[45], CD40L [46], TRAIL-DR5 [47], and many
more, have revealed that these cytokines recognise their ligands or receptor with specificity and in
most cases, exclusively [40,44]. In the present study, the potency of the rh OPG was significantly higher
than that of the peptides although this could be, in part, due to the fact that OPG interacts with RANKL
through multiple active sights and domains when compared to the peptides. However, the observed
potency of the OPG mimetic peptides, which are smaller molecules compared to the OPG ligand, may
indicate a higher degree of specificity that is enough for a desired effect of reducing osteoclastogenesis.
It is also worth noting that the dosage used for peptides and OPG was not equimolar. Therefore,
the data were not directly comparable due to the differences in the number of active domains and
molecular weight of the natural protein and of the synthetic peptides. As such, the cultures treated
with OPG should only be considered as a positive control.
The peptide is an OPG mimic designed to bind to RANKL and attenuate osteoclastogenesis.
This in vitro cell work demonstrated the theranostics potential of the peptide, DOTA-Gd-OP3-4,
in future clinical applications. However, in vivo evaluations of the peptide biodistribution, tissue
retention time, and bone targeting properties are necessary to inform on the safety and potential
clinical efficacy of the developed theranostics.
5. Conclusions
OPG mimetic peptide (OP3-4) and its novel derivatives DOTA-OP3-4 and MRI detectable DOTA
-Gd-OP3-4 were successfully synthesised with DOTA-Gd-OP3-4, showing a concentration-dependent
MRI T1 signal. The OP3-4 was found to be noncytotoxic on osteoblasts at the concentrations examined
and its derivatisation into DOTA-OP3-4 and DOTA-Gd-OP3-4 did not reduce cell viability. Moreover,
their potency in the inhibition of RANKL/M-CSF-induced osteoclastogenesis in monocytes was clearly
proven. Therefore, this work provides evidence in support of a novel theranostics tool for a more
efficient and specific treatment of metabolic bone diseases, such as osteoporosis and metastases.
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